Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff fiercepharma.com/marketing/bris…
FiercePharma
35.4K posts
FiercePharma
@FiercePharma
Pharma’s go-to destination for news & trends shaping approved drugs. Delivering news, revealing insights straight to your inbox.
- Daiichi's Plexxikon goes after Novartis cancer med Tafinlar in BRAF patent suit fiercepharma.com/legal/daiichi-…
- U.S. drugmakers chop fewer jobs this year despite headwinds fiercepharma.com/pharma/u-s-dru…
- Merck piles on the positive Keytruda-chemo combo results in lung cancer: fiercepharma.com/pharma/esmo-me… #ESMO17
- Growth-hungry Gilead finally pivots from flagging hep C with $12B Kite buy fiercepharma.com/pharma/gilead-…
- Will more pharmas defy Trump after Merck CEO's council exit? Don't count on it fiercepharma.com/pharma/other-d…
- Pfizer's AML med Mylotarg wins FDA approval for the second time
- FDA blesses nonprofit-backed Chagas drug, thwarting ex-Shkreli biotech’s bid for rival launch
- FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive problems fiercepharma.com/pharma-asia/fi…
- FDA slams Pfizer unit that made EpiPens that failed during fatal emergencies
- The Medicines Co. nets $400M nod for UTI antibacterial treatment fiercepharma.com/pharma/medicin…
- Can Novartis' Kisqali beat Pfizer's Ibrance to a NICE OK? fiercepharma.com/pharma/can-nov…
- New Hampshire, 'ground zero' of addiction epidemic, sues Purdue Pharma for overhyping opioids
